Literature DB >> 3286507

Elevated serum beta-2-microglobulin--a prognostic marker for development of AIDS among patients with persistent generalized lymphadenopathy.

J Morfeldt-Månson1, I Julander, L V von Stedingk, J Wasserman, B Nilsson.   

Abstract

For evaluation of its prognostic value, the level of serum beta-2-microglobulin was determined in early serum samples from 88 patients with persistent generalized lymphadenopathy in a prospective longitudinal study. Patients with serum beta-2-microglobulin greater than 2.6 mg/l were found to have a significantly higher risk of developing AIDS earlier when compared to patients with a lower level (p less than 0.001).

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 3286507     DOI： 10.1007/bf01644315

Source DB:  PubMed          Journal:  Infection        ISSN： 0300-8126            Impact factor:   3.553


  6 in total

1.  Beta 2-microglobulin as a prognostic marker for development of AIDS.

Authors:  R B Bhalla; B Safai; S Pahwa; M K Schwartz
Journal:  Clin Chem       Date:  1985-08       Impact factor: 8.327

2.  Classification system for human T-lymphotropic virus type III/lymphadenopathy-associated virus infections.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  1986-05-23       Impact factor: 17.586

3.  Serum neopterin and beta 2-microglobulin in anti-HIV positive blood donors.

Authors:  P Lambin; H Desjobert; M Debbia; J M Fine; J Y Muller
Journal:  Lancet       Date:  1986-11-22       Impact factor: 79.321

4.  Beta-2-microglobulin concentrations correlate with helper T cell counts in blood of homosexual men.

Authors:  B Petrini; L V von Stedingk; J Wasserman; L Morfeldt-Månsson; P Pehrson
Journal:  J Clin Lab Immunol       Date:  1984-09

5.  Serum beta-2 microglobulin levels in homosexual men with AIDS and with persistent, generalized lymphadenopathy.

Authors:  R L Burkes; A E Sherrod; M L Stewart; P S Gill; S Aguilar; C R Taylor; M D Krailo; A M Levine
Journal:  Cancer       Date:  1986-06-01       Impact factor: 6.860

6.  Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples.

Authors:  R Peto; M C Pike; P Armitage; N E Breslow; D R Cox; S V Howard; N Mantel; K McPherson; J Peto; P G Smith
Journal:  Br J Cancer       Date:  1977-01       Impact factor: 7.640
  6 in total
  4 in total

1.  Cerebrospinal fluid neopterin and beta 2-microglobulin levels in neurologically asymptomatic HIV-infected patients before and after initiation of zidovudine treatment.

Authors:  L Hagberg; G Norkrans; M Andersson; H Wachter; D Fuchs
Journal:  Infection       Date:  1992 Nov-Dec       Impact factor: 3.553

Review 2.  Recent advances in the medical management of early HIV disease.

Authors:  P A Volberding
Journal:  J Gen Intern Med       Date:  1991 Jan-Feb       Impact factor: 5.128

3.  Correlation of serum B lymphocyte stimulator and beta2 microglobulin with autoantibody secretion and systemic involvement in primary Sjogren's syndrome.

Authors:  J-E Gottenberg; M Busson; J Cohen-Solal; F Lavie; K Abbed; R P Kimberly; J Sibilia; X Mariette
Journal:  Ann Rheum Dis       Date:  2005-01-07       Impact factor: 19.103

4.  Prevalence of antibodies to human herpesviruses and hepatitis B virus in patients at different stages of human immunodeficiency virus (HIV) infection.

Authors:  R Enzensberger; W Braun; C July; E B Helm; H W Doerr
Journal:  Infection       Date:  1991 May-Jun       Impact factor: 3.553
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.